Submit Manuscript  

Article Details

CD28: A New Drug Target for Immune Disease


Sijing Xia, Qin Chen and Bing Niu*   Pages 1 - 10 ( 10 )


Background: CD28, a cell surface glycoprotein receptor, predominantly expressed on activated T cells, belongs to the Ig superfamily and can provides a critical co-stimulatory signal. CTLA-4 has sequence homology to CD28, is expressed on T cells after activation. It provides an inhibition signal coordinated with CD28 to regulate T cell activation. Both of them regulate T cell proliferation and differentiation, and play an important role in the immune response pathway in vivo.

Objective: We studied the special role of different structural sites of CD28 in producing costimulatory signals.

Method: We reviewed the relevant literature, mainly from the structure of CD28 to clarify its biological function, and its role in the immune response.

Results: In recent years, increasingly attention has been paid to CD28, which is considered as a key therapeutic target for many modern diseases, especially some immune diseases.

Conclusion: In this paper, we mainly introduce the structure of CD28 and its related biological functions, as well as the application of costimulatory pathways targeting CD28 in disease treatment.


Ligands , CTLA-4, Structure, Immune Response, Transplant rejection, Malignant tumor, Systemic lupus erythematosus, Rheumatoid arthritis Ligands, Rheumatoid arthritis


College of Life Science, Shanghai University, Shanghai, College of Life Science, Shanghai University, Shanghai, College of Life Science, Shanghai University, Shanghai

Read Full-Text article